Response and resistance to targeted therapy in renal cell carcinoma
Research type
Research Study
Full title
Response and resistance to targeted therapy in renal cell carcinoma
IRAS ID
80475
Contact name
Samra Turajlic
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Renal cell carcinoma (RCC) is diagnosed in approximately 8000 people in the United Kingdom every year. The mainstay of curative treatment for primary disease is surgery i.e. nephrectomy to remove the primary lesion.\n\nApproximately half of RCC tumours have mutations in the von Hippel-Lindau gene (VHL). VHL loss increases expression of the hypoxia-inducible transcription factors known as HIF-1Ą and HIF-2Ą. These factors regulate the expression of vascular endothelial growth factor (VEGF) and other molecules implicated in angiogenesis and invasion. These pathways are important in the pathophysiology of RCC although their roles are incompletely understood.\n\nThere is a need to (a) understand better the biology of renal cell carcinoma, (b) develop predictive and prognostic biomarkers, and (c) identify new therapeutic targets for this disease. Aberrant kinase signalling is important in RCC and kinase inhibitors are active in the treatment of metastatic disease. By obtaining samples (a) at presentation, prior to any neoadjuvant therapy, (b) at nephrectomy, (c) at follow up, and (d) at progression, we aim to (1) monitor the progression of disease over time, (2) study the mechanisms of response and resistance to treatment, (3) identify new therapeutic targets. The collection of fresh nephrectomy material in particular provides the opportunity to study fresh tissue, much of which is surplus to diagnostic requirements. [COVID-19 amendment 30/04/2020] Section A10, A11, A12 & A13- Addition of CAPTURE sub-study. Updated endpoints and trial design. A15. CAPTURE sub-study include: Group A: Cancer patients with SARS-CoV-2 Group B: Cancer patients no clinical indication of SARS-CoV-2 Group C: Volunteers without cancer with SARS-CoV-2 (Hospital staff)\nA17: Addition of CAPTURE sub-study inclusion & exclusion criteria\nA27: Group C/volunteer group- adverts will be sent out via the internal communications team and/or listed on internal electronic staff boards.A27: Information regarding the trial will be available on a web page build by the Royal Marsden digital team.\nA59: CAPTURE sub-study recruitment target: 2,400 participants Part B Section Q1- Collection of nose swabs.
REC name
London - Fulham Research Ethics Committee
REC reference
11/LO/1996
Date of REC Opinion
17 Jan 2012
REC opinion
Further Information Favourable Opinion